Steegen K, Hans L. Compelling evidence for unconditional shift to dolutegravir. Lancet HIV. 2022;9(8):e523-e4. https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(22)00164-3/fulltext
Compelling evidence for unconditional shift to dolutegravir.
By Peter Matlawa|2023-03-01T09:25:31+02:00March 1, 2023|2022: July to September|Comments Off on Compelling evidence for unconditional shift to dolutegravir.
Share This Story, Choose Your Platform!
About the Author: Peter Matlawa
Related Posts
Performance of glucagon stimulation test in diagnosing central adrenal insufficiency in children when utilising the Roche Elecsys(®) cortisol II assay: a pilot study.